NEOK Bio vs Genentech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Genentech leads in AI visibility (85 vs 27)
NEOK Bio logo

NEOK Bio

EmergingBioTech

Neuroscience

NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of innate immune modulators.

AI VisibilityBeta
Overall Score
D27
Category Rank
#2 of 2
AI Consensus
56%
Trend
up
Per Platform
ChatGPT
34
Perplexity
18
Gemini
36

About

NEOK Bio is targeting neuroinflammation — the chronic activation of brain immune cells (microglia and astrocytes) — as a primary driver of neurodegeneration in Alzheimer's disease, ALS, and Parkinson's disease. The company's small molecule drug candidates modulate the NLRP3 inflammasome and related innate immune pathways in the brain, aiming to reduce the toxic inflammatory environment that kills neurons over time.

Full profile
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
A85
Category Rank
#1 of 2
AI Consensus
57%
Trend
up
Per Platform
ChatGPT
77
Perplexity
95
Gemini
83

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile

AI Visibility Head-to-Head

27
Overall Score
85
#2
Category Rank
#1
56
AI Consensus
57
up
Trend
up
34
ChatGPT
77
18
Perplexity
95
36
Gemini
83
28
Claude
87
33
Grok
79

Key Details

Category
Neuroscience
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only NEOK Bio
Neuroscience
Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.